pharma · Generalized Pustular Psoriasis · Schizophrenia · VNDA
Vanda Pharmaceuticals Netherlands
Vanda Pharmaceuticals Netherlands B.V.
Vanda Pharmaceuticals Netherlands is a pharma organization headquartered in Washington, USA. It trades on NYSE under ticker VNDA. Primary therapeutic focus areas include Generalized Pustular Psoriasis, Schizophrenia, Maj
2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US HQ
2003 Founded
600 Employees
Public company Type
VNDA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US
- Founded
- 2003
- Employees
- 600
- Programs
- 60
- Drugs
- 19
- Patents
- 96
VLY-686
Phase 2 · small molecule · Treatment-resistant Pruritus Associated With Atopic Dermatitis
VLY-686 for Treatment-resistant Pruritus Associated With Atopic Dermatitis is a Phase 2 program (small_molecule) at Vanda Pharmaceuticals Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Internal code VP-VLY-686-2101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vanda Pharmaceuticals Netherlands B.V.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Treatment-resistant Pruritus Associated With Atopic Dermatitis
- Status
- completed
- Trials
- 1